FDA Approves Pfizer, Moderna’s Newly Formulated COVID Vaccines That Specifically Address Omicron Variant

New COVID-19 vaccines are anticipated to be released this month. However, the new formula reportedly doesn't offer protection against the original variant.

Pfizer, Moderna's New COVID Vaccines Approved

Newly created COVID vaccines from Pfizer and Moderna have received approval from the Food and Drug Administration (FDA). Unlike the previous booster injections, this vaccine was not created using ingredients from the original COVID variations that became widespread in 2020. An omicron subvariant is the target of the monovalent vaccine.

The new vaccines notably target the omicron variant XBB.1.5, which, according to CDC statistics, overtook EG.5 as the predominant COVID strain in some regions of the US last winter and is responsible for 21.5 percent of cases.

While the FDA approved the vaccines for use in persons 12 years of age and older, it also granted permission for youngsters between the ages of six months and 11 to receive the shots in an emergency due to the change. The earlier boosters from Moderna and Pfizer can no longer be used.

The new immunizations are "expected to provide good protection against COVID-19 from the currently circulating variants," according to the FDA, which also cautions that the "composition" of the shots may require annual revisions in the future, just like the flu vaccines do.

The Centers for Disease Control and Prevention will discuss immunization recommendations on Tuesday. By the end of this week, the vaccine might be accessible to the general population if the CDC releases its recommendations tomorrow.

ALSO READ: COVID-19 Spike: Coronavirus Cases Increase by 12% This Summer

Fall COVID Booster

The new vaccine is expected to be released in mid-September. However, certain groups of individuals expected to benefit more from it.

Less evidence supports the potential advantages of a second booster for healthy individuals under 65 who have already had a vaccine or are unwell. The fall COVID booster would be most beneficial to persons 65 and older and those chronically ill, immunosuppressed, or pregnant.

Jennifer Nuzzo, a professor of epidemiology and the director of the Pandemic Center at the Brown University of Public Health, acknowledged that she is constantly concerned for the people who would gain the most from boosters, particularly those who are at high risk for serious illness, those who are 65 years of age and older, as well as those who have underlying medical conditions.

The head of the Center for Vaccination Education at Children's Hospital of Philadelphia, Dr. Paul Offit, agrees. According to Offit, we should focus on the most susceptible people. Not all diseases are meant to be wiped out. Instead, avoiding hospitalizations is the goal, he added.

Stanley Perlman, a professor of microbiology and immunology at the University of Iowa Carver College of Medicine, also said infants who are at least six months old and have not had the initial dose of the COVID-19 vaccine are also at increased risk for contracting the illness. They might gain something from getting it.

Furthermore, according to Nuzzo, the situation is a bit more complicated, and everyone else's benefits are less evident. There is proof that temporary boosting increases antibody levels, which may be beneficial. However, she advises waiting to see what the CDC says about the new vaccine.